Immunocompetent nontransgenic mouse models for studying hepatitis B virus immune responses

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue SUPPL 1, 2013, Pages 116-119

  Tzeng, Horng Tay ^b   Hsu, Ping Ning ^a,b   Chen, Pei Jer ^b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Hepatitis B virus; Immune response; Mouse animal model

Indexed keywords

ADENOVIRUS VECTOR; CXCL3 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; HEPATITIS B CORE ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; SMALL INTERFERING RNA; VIRUS DNA;

ADAPTIVE IMMUNITY; ANTIBODY PRODUCTION; CYTOKINE PRODUCTION; GENE EXPRESSION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; INNATE IMMUNITY; LIVER CELL; LIVER CELL CARCINOMA; LIVER TUMOR; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRAL CLEARANCE; VIRION; VIRUS GENOME;

EID: 84984577973     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12035     Document Type: Review

References (38)

1. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu. Rev. Immunol. 1995; 13: 29-60.
2. Jung MC, Pape GR. Immunology of hepatitis B infection. Lancet Infect. Dis. 2002; 2: 43-50.
3. Chisari FV, Pinkert CA, Milich DR etal. A transgenic mouse model of the chronic hepatitis B surface antigen carrier state. Science 1985; 230: 1157-1160.
4. Moriyama T, Guilhot S, Klopchin K etal. Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus transgenic mice. Science 1990; 248: 361-364.
5. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat. Rev. Immunol. 2005; 5: 215-229.
6. Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther. 1999; 6: 1258-1266.
7. Herweijer H, Wolff JA. Gene therapy progress and prospects: hydrodynamic gene delivery. Gene Ther. 2007; 14: 99-107.
8. Zhang G, Ludtke JJ, Thioudellet C etal. Intraarterial delivery of naked plasmid DNA expressing full-length mouse dystrophin in the mdx mouse model of duchenne muscular dystrophy. Hum. Gene Ther. 2004; 15: 770-782.
9. Yang PL, Althage A, Chung J, Chisari FV. Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection. Proc. Natl Acad. Sci. U.S.A. 2002; 99: 13825-13830.
10. Huang LR, Wu HL, Chen PJ, Chen DS. An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection. Proc. Natl Acad. Sci. U.S.A. 2006; 103: 17862-17867.
11. Riu E, Grimm D, Huang Z, Kay MA. Increased maintenance and persistence of transgenes by excision of expression cassettes from plasmid sequences in vivo. Hum. Gene Ther. 2005; 16: 558-570.
12. Chen SH, Wu HL, Kao JH, Hwang LH. Persistent hepatitis B viral replication in a FVB/N mouse model: impact of host and viral factors. PLoS ONE 2012; 7: e36984.
13. Tzeng HT, Tsai HF, Liao HJ etal. PD-1 blockage reverses immune dysfunction and hepatitis B viral persistence in a mouse animal model. PLoS ONE 2012; 7: e39179.
14. Yang PL, Althage A, Chung J etal. Immune effectors required for hepatitis B virus clearance. Proc. Natl Acad. Sci. U. S. A. 2010; 107: 798-802.
15. Hosel M, Quasdorff M, Wiegmann K etal. Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection. Hepatology 2009; 50: 1773-1782.
16. Lutgehetmann M, Bornscheuer T, Volz T etal. Hepatitis B virus limits response of human hepatocytes to interferon-alpha in chimeric mice. Gastroenterology 2011; 140: 2074-2083, 83 e1-2.
17. Yin W, Xu L, Sun R, Wei H, Tian Z. Interleukin-15 suppresses hepatitis B virus replication via IFN-beta production in a C57BL/6 mouse model. Liver Int. 2012; 32: 1306-1314.
18. Fisicaro P, Valdatta C, Boni C etal. Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut 2009; 58: 974-982.
19. Lin YJ, Huang LR, Yang HC etal. Hepatitis B virus core antigen determines viral persistence in a C57BL/6 mouse model. Proc. Natl Acad. Sci. U. S. A. 2010; 107: 9340-9345.
20. Lin YJ, Wu HL, Chen DS, Chen PJ. Hepatitis B virus nucleocapsid but not free core antigen controls viral clearance in mice. J. Virol. 2012; 86: 9266-9273.
21. Keasler VV, Hodgson AJ, Madden CR, Slagle BL. Enhancement of hepatitis B virus replication by the regulatory X protein in vitro and in vivo. J. Virol. 2007; 81: 2656-2662.
22. Keng VW, Tschida BR, Bell JB, Largaespada DA. Modeling hepatitis B virus X-induced hepatocellular carcinoma in mice with the Sleeping Beauty transposon system. Hepatology 2011; 53: 781-790.
23. Kumar M, Jung SY, Hodgson AJ, Madden CR, Qin J, Slagle BL. Hepatitis B virus regulatory HBx protein binds to adaptor protein IPS-1 and inhibits the activation of beta interferon. J. Virol. 2011; 85: 987-995.
24. Ebert G, Poeck H, Lucifora J etal. 5′ Triphosphorylated small interfering RNAs control replication of hepatitis B virus and induce an interferon response in human liver cells and mice. Gastroenterology 2011; 141: 696-706, e1-3.
25. Han Q, Zhang C, Zhang J, Tian Z. Reversal of hepatitis B virus-induced immune tolerance by an immunostimulatory 3p-HBx-siRNAs in a retinoic acid inducible gene I-dependent manner. Hepatology 2011; 54: 1179-1189.
26. Bramson JL, Graham FL, Gauldie J. The use of adenoviral vectors for gene therapy and gene transfer in vivo. Curr. Opin. Biotechnol. 1995; 6: 590-595.
27. Shayakhmetov DM, Gaggar A, Ni S, Li ZY, Lieber A. Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J. Virol. 2005; 79: 7478-7491.
28. Hartman ZC, Kiang A, Everett RS etal. Adenovirus infection triggers a rapid, MyD88-regulated transcriptome response critical to acute-phase and adaptive immune responses in vivo. J. Virol. 2007; 81: 1796-1812.
29. Liu Q, Zaiss AK, Colarusso P etal. The role of capsid-endothelial interactions in the innate immune response to adenovirus vectors. Hum. Gene Ther. 2003; 14: 627-643.
30. Huang LR, Gabel YA, Graf S etal. Transfer of HBV genomes using low doses of adenovirus vectors leads to persistent infection in immune competent mice. Gastroenterology 2012; 142: 1447-1503.
31. von Freyend MJ, Untergasser A, Arzberger S etal. Sequential control of hepatitis B virus in a mouse model of acute, self-resolving hepatitis B. J. Viral Hepat. 2011; 18: 216-226.
32. Goncalves MA. Adeno-associated virus: from defective virus to effective vector. Virol. J. 2005; 2: 43.
33. Breous E, Somanathan S, Wilson JM. BALB/c mice show impaired hepatic tolerogenic response following AAV gene transfer to the liver. Mol. Ther. 2010; 18: 766-774.
34. Mingozzi F, Liu YL, Dobrzynski E etal. Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J. Clin. Invest. 2003; 111: 1347-1356.
35. Huang YH, Fang CC, Tsuneyama K etal. A murine model of hepatitis B-associated hepatocellular carcinoma generated by adeno-associated virus-mediated gene delivery. Int. J. Oncol. 2011; 39: 1511-1519.
36. Racz Z, Godo M, Revesz C, Hamar P. Immune activation and target organ damage are consequences of hydrodynamic treatment but not delivery of naked siRNAs in mice. Nucleic Acid Ther. 2011; 21: 215-224.
37. Hartman ZC, Appledorn DM, Amalfitano A. Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Res. 2008; 132: 1-14.
38. Breous E, Somanathan S, Vandenberghe LH, Wilson JM. Hepatic regulatory T cells and Kupffer cells are crucial mediators of systemic T cell tolerance to antigens targeting murine liver. Hepatology 2009; 50: 612-621.